HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDEN TIAL AND PROPRIETARY  1  STATISTICAL ANALYSIS PLAN  
PHASE II  
 
VERSION: 2.0 
DATE OF PLAN:  
APRIL 11 , 201 9 
 
BASED ON:  
Protocol V2.0 
CRF V2.0 
 
STUDY DRUG:  
BioThrax¬Æ 
AV7909 
PROTOCOL NUMBER:  
BP-C-17001  
STUDY TITLE:  
Randomized, Active -Comparison, Double -Blind, Phase 2 Study to Assess the Safety and 
Immunogenicity of Anthrax Vaccine Adsorbed (BioThrax¬Æ) without and with CPG 7909 
Adjuvant (AV7909 Anthrax Vaccine), Using a Post Exposure Prophylaxis Dosing Regimen in 
Adul ts 66 Years of Age or Older in Stable Health in Comparison to Adults 18 50 Years of Age 
in Stable Health  
SPONSOR:  
Biomedical Advanced Research and Development Authority (BARDA)  
 
 
 
This study is being conducted in compliance with good clinical practice, including the archiving 
of essential documents.  
 

HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  2  
   
    SIGNATURE PAGE  
This document has been reviewed and accepted by:  
 
     
 
Rho  Signature   Date  
     
 
 
Biomedical Advanced Research and  
Development Authority (BARDA)   Signature   Date  
 
Document History  
Version Date Change(s)  Author 
1.0 28 Jun 2018  Initial Version   
2.0 11 Apr 2019  Added defin itions for seroconversion 
using TNA ED50 and ELISA anti -PA 
IgG; replace LLOD/ULOD with 
LLOQ/ULOQ ; updated IPPP 
population protocol deviation criteria;  
added modified IPPP and 
corresponding analyses ; added a 
column for MIPPP visit windows; 
deleted imputation methods for 
immunogenicity data; fixed minor 
grammatical errors; added exploratory 
immunogenicity comparisons; added 
AE tables by dose; modified blinding of 
AE and other tables for interim 
analys is; added solicited systemic 
reactogenicity symptoms by 
relationship tables; updated wording of 
safety and IFAP populations to include 
incorrectly randomized subjects; 
updated list of interim analysis tables; 
added clarification of SMC interim 
report; adde d criteria for using low 
level term instead of preferred term for 
some events   

HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  3  
   
     
TABLE OF CONTENTS  
STATISTICAL ANALYSIS  PLAN  ................................ ................................ ................................ 1 
SIGNATURE PAGE  ................................ ................................ ................................ ....................... 2 
LIST OF TABLES  ................................ ................................ ................................ ........................... 7 
1. LIST OF ABBREVIATION S ................................ ................................ ....................... 8 
2. INTRODUCTION  ................................ ................................ ................................ ......10 
3. STUDY OBJECTIVES  ................................ ................................ .............................. 11 
3.1. Primary Objectives  ................................ ................................ ................................ .....11 
3.1.1.  Safety  ................................ ................................ ................................ .......................... 11 
3.1.2.  Immu nogenicity  ................................ ................................ ................................ .......... 11 
3.2. Secondary Objective  ................................ ................................ ................................ ...11 
3.2.1.  Safety  ................................ ................................ ................................ .......................... 11 
3.2.2.  Immunogenicity  ................................ ................................ ................................ .......... 11 
4. STUDY DESIGN  ................................ ................................ ................................ .......13 
4.1. Sample Size Justification  ................................ ................................ ............................ 14 
5. STUDY DURATION AND V ISIT SCHEDULE  ................................ ...................... 16 
6. CLINICAL ASSESSMENTS  ................................ ................................ ..................... 17 
6.1. Screening and Baseline Assessments  ................................ ................................ ......... 17 
6.2. Post-Baseline Assessments  ................................ ................................ ......................... 17 
6.3. Final Evaluation or Early Termination Visit  ................................ .............................. 18 
7. DEFINITION S AND CONVENTIONS  ................................ ................................ ....19 
7.1. General Summary Table and Individual Subject Data Listing Considerations  .......... 19 
7.1.1.  Imputation of Missing Data  ................................ ................................ ........................ 20 
7.2. Calculations Using Dates  ................................ ................................ ............................ 20 
7.3. Baseline  ................................ ................................ ................................ ....................... 20 
7.3.1.  Visit Windows Relative to the First Dose of Study Medication  ................................ 20 
7.4. Analysis Populations  ................................ ................................ ................................ ..22 
7.4.1.  Screen Failures  ................................ ................................ ................................ ............ 22 
7.4.2.  Randomized Population  ................................ ................................ .............................. 22 
7.4.3.  Safety Population  ................................ ................................ ................................ ........ 22 
7.4.4.  Immunogenicity Full Analysis Population  ................................ ................................ .22 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  4  
   
    7.4.5.  Immunogenicity Per Protocol Population  ................................ ................................ ...23 
7.4.6.  Modified  Immunogenicity Per Protocol Population  ................................ ................... 23 
8. DATA PRESENTATIONS A ND DATA MANAGEMENT  ................................ .....24 
8.1. Data Presentations  ................................ ................................ ................................ ......24 
8.2. Data Management  ................................ ................................ ................................ .......24 
8.3. General Post Text Summary Table and Individual Subject Data Listing 
Format Considerations  ................................ ................................ ................................ 24 
9. SUBJECT ACCOUNTING A ND DEMOGRAPHIC PROFI LE OF 
SCREEN FAILURES  ................................ ................................ ................................ .25 
9.1. Subject Accounting by Treatment Group and Sex  ................................ ..................... 25 
9.2. Subject Distribution by Site  ................................ ................................ ........................ 25 
9.3. Screen Failures  ................................ ................................ ................................ ............ 25 
10. SUBJECT DISPOSITION  ................................ ................................ .......................... 26 
11. BASELINE SUBJECT DAT A ................................ ................................ ................... 27 
11.1.  Baseline Demographic and Physical Characteristics  ................................ .................. 27 
11.1.1. Listing of Subject Inclusion and Exclusion Criteria  ................................ ................... 27 
11.2.  Medical History and Medical Conditions Present at Entry  ................................ ........ 27 
11.3.  Prior Medication History and Medications Present at Entry  ................................ ......27 
11.4.  Screening Laboratory Data  ................................ ................................ ......................... 28 
12. IMMUNOGENICITY  ................................ ................................ ................................ 29 
12.1.  General Considerations  ................................ ................................ ............................... 29 
12.2.  Statement of the Null and Alternate Hypotheses  ................................ ........................ 29 
12.3.  Subgroup Analyses  ................................ ................................ ................................ .....30 
12.4.  Multiple Comparisons and Multip licity  ................................ ................................ ......30 
12.5.  Analysis of the Primary Immunogenicity Endpoint  ................................ ................... 30 
12.6.  Analysis of the Secondary Immunogenicity Endpoints  ................................ .............. 30 
12.6.1.  Presentation of the Secondary Immunogenicity Results  ................................ ............ 31 
12.6.1.1.  Antibody Levels  ................................ ................................ ................................ .......... 31 
12.6.1.2.  Seroprotection and Seroconversion Rates  ................................ ................................ ..31 
12.7.  Analy sis of the Exploratory Immunogenicity Endpoints  ................................ ........... 32 
12.7.1.  Antibody level correlations  ................................ ................................ ......................... 32 
12.7.2.  Additional pairwise comparisons  ................................ ................................ ............... 32 
13. SAFETY AND TOLERABIL ITY ................................ ................................ .............. 33 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  5  
   
    13.1.  Overall Summary of Tolerability  ................................ ................................ ................ 33 
13.2.  Adverse Event Preferred Term and System Organ Class Summary Tables  ............... 33 
13.2.1.  Summaries of Adverse Event Incidence Rates for All Subjects  ................................ .34 
13.2.2.  Missing and Partial AE Onset Dates  ................................ ................................ .......... 35 
13.2.3.  Early Termination of Investigational Product due to Adverse Event, Subject 
Study Withdrawal due to Adverse Event, and Death  ................................ ................. 36 
13.3.  Pregnancy Monitoring and Assessment  ................................ ................................ ......36 
13.4.  Safety Endpoint Analyses  ................................ ................................ ........................... 36 
13.4.1. General Considerations  ................................ ................................ ............................... 36 
13.4.2.  Statement of the Null and Alternate Hypotheses  ................................ ........................ 36 
13.4.3.  Subgroup Analyses  ................................ ................................ ................................ .....36 
13.4.4.  Analysis of the Primary Safety Endpoint  ................................ ................................ ...36 
13.4.5.  Analysis of the Secondary Safety Endpoints  ................................ .............................. 37 
13.4.6.  Summary of Reasons for Safety Non -evaluability/Exclusion from Safety 
Analyses  ................................ ................................ ................................ ...................... 37 
13.5.  Investigational Product Administration Compliance  ................................ .................. 37 
13.6.  Concomitant and Other Medications  ................................ ................................ .......... 37 
13.6.1.  Missing and Partial Concomitant and Other Medication Start and Stop Dates  .......... 38 
13.7.  Investigational Product Administration Site Examination  ................................ ......... 38 
13.8.  Diary Card Measurements  ................................ ................................ .......................... 39 
13.9.  Clinical Laboratory Data  ................................ ................................ ............................ 39 
13.10.  Vital Signs  ................................ ................................ ................................ .................. 39 
13.11.  Physical E xamination  ................................ ................................ ................................ .40 
13.12.  Other Safety Assessments  ................................ ................................ ........................... 40 
13.13.  Subject Study Withdrawal Status  ................................ ................................ ............... 40 
14. PROTOCOL DEVIATIONS  ................................ ................................ ...................... 41 
15. MAINTAINING THE BLIN D ................................ ................................ ................... 42 
15.1.  Imm unogenicity Data  ................................ ................................ ................................ .42 
16. INTERIM ANALYSES  ................................ ................................ .............................. 43 
17. SAFETY MONITORING CO MMITTEE MEETINGS  ................................ ............ 44 
18. CHANGES TO COMPLETED  REPORTS  ................................ ................................ 45 
19. REFERENCES  ................................ ................................ ................................ ........... 46 
20. APPENDIX  ................................ ................................ ................................ ................. 47 
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  6 20.1.  Table of Contents for Data Display Specifications  ................................ .................... 47 
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  7 LIST OF TABLES  
Table  1: Study Groups  ................................ ................................ ................................ .............. 13 
Table  2: Probability of Observing at Least 1 Safety Event of Interest under Different 
True Event Rates  ................................ ................................ ................................ ......... 14 
Table  3: Power for Detecting a Lower 95% Confidence Limit of ‚â•40% about an 
Observed Seroprotection Rate  ................................ ................................ .................... 15 
Table  4: Visit Schedule  ................................ ................................ ................................ ............. 21 
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  8 1. LIST OF ABBREVIATION S 
Abbreviation  Term 
ADaM  Analysis Data Model  
AE adverse event 
ATC Anatomical Therapeutic Chemical  
AV7909  AV7909 Anthrax Vaccine 
BARDA  Biomedical Advanced Research  and Development Authority  
BMI  body mass index  
B-SAFE  BARDA Securing Anthrax Immunity For the Elderly  
CI confidence interval  
CSR  Clinical Study Report  
DOB  date of birth 
DSMP  Data Safety Monitoring Plan  
ECG  electrocardiogram  
eCRF  electronic case report form  
ED 50 effective dilution resulting in 50% neutralization  
EDC  electronic data capture  
ELISA  enzyme -linked immunosorbent assay  
GM geometric mean  
H0 null hypothesis  
HA alternative hypothesis  
HbA1 C hemoglobin A1 C 
HBV  hepatitis B vaccine  
HCV  hepatitis C vaccine  
HEENT  head, eyes, ears, nose and throat  
HIV human immunodeficiency virus  
hs-CRP  high-sensitivity C -reactive protein  
ID identification number  
IFAP  immunogenicity full analysis population  
IgG immunoglobulin G  
IM intramuscular  
IP investigational product  
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  9 IPPP  immunogenicity per protocol population  
LLOQ  lower limit of quantitation  
MAAE medically  attended adverse event  
max maximum  
MCMC  Markov chain Monte Carlo  
MedDRA  Medical Dictionary for Regulatory Activities Terminology  
min minimum  
MIPPP  modified immunogenicity per protocol population  
NF 50 50% neutralization factor  
OC observed cases 
PA protective antigen  
PIMMC  potentially immune -mediated medical condition  
PT preferred term 
SAE  serious adverse e vent 
SAP Statistical Analysis Plan  
SC subcutaneous  
SCR  seroconversion rate  
SD standard deviation  
SDTM  Study Data Tabulation Model  
SI International System of Units  
SMC  Safety Monitoring Committee  
SOC  system organ class 
SPR seroprotection rate  
TNA  toxin neutralization antibody  
ULOQ  upper limit of quantitation  
WHO  World Health Organization  
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  10 2. INTRODUCTION  
The purpose of this statistical analysis plan (SAP) is to describe the planned analyses and data 
displays to be included in the  interim analysis and  Clinical Study Report ( CSR) for Protocol 
BP-C-17001.   Additionally, this document provides details on study populations and on how the 
variables will be derived, how missing data will be handled as well as details on statistical 
methods to be used to analyze the safety a nd immunogenicity data  
All decisions regarding fina l analysis, as defined in this S AP document, will be made prior to 
Database Freeze (unblinding) of the study data. Further information can be found in the protocol.  
Deviations from the final approved SAP will be no ted in the CSR . 
If additional analyses are required to supplement the planned analyses described in this SAP, 
they will be identified in the CSR.  Table, figure, and listing specifications are provided in 
separate documents.  
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  11 3. STUDY OBJECTIVES  
3.1. Primary Objective s 
3.1.1. Safety 
ÔÇ∑To evaluate safety and reactogenicity, as determined by solicited local and systemic
reactogenicity symptoms (within 8 days after each vaccination, inclusive of the
vaccination day , excluding reactogenicity on the contralateral ar m), of BioThrax or
AV7909 administered to adults ‚â•66 years of age.
3.1.2. Immunogenicity  
ÔÇ∑To evaluate the seroprotection, defined as toxin neutralization antibody ( TNA ) 50%
neutralization factor  (NF 50) ‚â•0.56, rate at Day 64 for BioThrax or AV7909 administered
to adults ‚â•66 years of age.
3.2. Secondary Objective  
3.2.1. Safety 
ÔÇ∑To evaluate the occurrence of treatment -emergent unsolicited adverse events (AEs)
(defined as all AEs other than solicited local and systemic reactogenicity symptoms ),
serious adverse events ( SAEs ), and medically attended adverse events (MAAEs),
including potentially immune -mediated medical conditions (PIMMCs) from the time of
the first dose of study  investigational product  (IP) through 12 months following the last
dose of study IP.
ÔÇ∑To evaluate the occurr ence of solicited local reactogenicity symptoms on the contralateral
arm (within 8 days after each vaccination, inclusive of the vaccination day).
3.2.2. Immunogenicity  
ÔÇ∑To assess the TNA NF 50 antibody levels, seroprotection rates, and seroconversion
(defined as a  ‚â•4-fold increase over baseline levels, or a ‚â•4 -fold increase over the lower
limit of quantitation [LLOQ] if the baseline value is < LLOQ) rates for each study group
at each applicable timepoint through Day 394.
ÔÇ∑To assess the TNA effective dilution resul ting in 50% neutralization (ED 50) antibody
levels and seroconversion rates  (defined as a ‚â•4 -fold increase over baseline levels, or a
‚â•4-fold i ncrease over LLOQ  if the baseline value is < LLOQ)  for each study group at
each applicable timepoint through Day 39 4.
ÔÇ∑To assess the enzyme -linked immunosorbent assay (ELISA) anti -protective antigen ( PA)
immunoglobulin G ( IgG) antibody levels and seroconversion  (defined as a ‚â•4 -fold
increase over baseline levels, or a ‚â•4 -fold i ncrease over  LLOQ  if the baseline value is <
LLOQ)  rates for each study group at each applicable timepoint through Day 394.
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  12 ÔÇ∑To compare the TNA NF 50 antibody levels, seroprotection rates, and seroconversion rates
through Day 394 between younger adults (18 through 50 years) and older adults
(‚â•66 years of age) within the following groups at each applicable timepoint:
1.BioThrax given at Days 1, 15, and 29
2.AV7909 given at Days 1 and 15 and placebo given at Day 29
ÔÇ∑To compare the TNA ED 50 antibody levels and seroconversion rates through Day 394
betwee n younger adults (18 through 50 years) and older adults (‚â•66 years of age) within
the following groups at each applicable timepoint:
1.BioThrax given at Days 1, 15, and 29
2.AV7909 given at Days 1 and 15 and placebo given at Day 29
ÔÇ∑To compare the ELISA anti -PA IgG antibody levels and seroconversion rates through
Day 394 between younger adults (18 through 50 years) and older adults (‚â•66 years of
age) within the following groups at each applicable timepoint:
1.BioThrax given at Days 1, 15, and 29
2.AV7909 given at  Days 1 and 15 and placebo given at Day 29
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  13 4. STUDY D ESIGN 
This is a phase 2, randomized, active -controlled, double -blinded, multi -site study to assess the 
safety and immunogenicity of BioThrax and AV7909 using a PEP dosing regimen in adults 
‚â•66 years of age in stable health.  The safety and immunogenicity profile of BioThrax and 
AV7909 in adults ‚â•66 years of age will also be compared to the safety and immunogenicity 
profile of subjects 18 through 50 years of age in stable health.  The main study goal is to 
determine optimal dosing for AV7909.   
Approximately 300 male and nonpregnant female adults (200 aged ‚â•66 years and 100 aged 18 
through 50 years, inclusive) will be enrolled in the study.    
After screening,  subjects meeting all of the inclusion criteria and none of the exclusion criteria 
will be randomized to receive either BioThrax or AV7909.  Randomizatio n will be stratified by 
sex and age (18 -50, 66 -74, and ‚â•75  years) .  Subjects ‚â•66 years of age will be randomized 1:1:1:1 
within stratum across 4  treatment arms  (approximately 50 subjects per group) , and subjects 18  
through 50 years of age will be randomized 1:1 within stratum across 2 treatment  arms 
(approximately 50 subjects per group) as specified in Table  1.  Once randomized, subjects will 
receive 3 IP administrations , each separated by approximately 14 days, on Day 1, Day  15, and 
Day 29, based on their assigned treatment arm.   
Table 1: Study Groups  
Study 
Group Number of 
Subjects Age 
Group Arm Investigational 
Product Route Dose 1 
Day 1 Dose 2 
Day 15 Dose 3 
Day 29 
Group 1  50 Age ‚â•66  1 BioThrax  SC BioThrax  BioThrax  BioThrax  
Group 2  50 Age ‚â•66  2 AV7909  IM AV7909  AV7909  AV7909  
Group 3  50 Age ‚â•66  3 AV7909  IM AV7909  AV7909  Placebo  
Group 4  50 Age ‚â•66  4 AV7909  IM AV7909  Placebo  AV7909  
Group 5  50 Age 18 -50 1 BioThrax  SC BioThrax  BioThrax  BioThrax  
Group 6  50 Age 18 -50 3 AV7909  IM AV7909  AV7909  Placebo  
Note: SC = subcutaneous; IM = intramuscular  
Immunogenicity assessments will include TNA NF 50, TNA ED 50, and ELISA anti -PA IgG 
antibody levels . 
Safety assessments will be based on solicited AEs (local and systemic reactogenicity symptoms) 
occurrin g within 8 days of each IP administration , treatment -emergent unsolicited AEs occurring 
through Day 50, and treatment -emergent SAEs, MAAEs, and PIMMCs throughout the study.  
Safety for each subject will be assessed from the time of the first dose of IP thro ugh 12 months 
following the last dose of IP.   
The expected study duration is approximately 1 4 months per subject.  
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  14 4.1. Sample Size Justification  
The sample size for this study is approximately 300 subjects: 200 subjects ‚â•66 years of age 
(older cohort) and 100  subjects 18 through 50 years of age (younger cohort).  Approximately 
50 subjects will be randomized into each of 6 study groups.  
The proposed sample size for this study is based on previous experience with similar BioThrax 
studies in individuals aged 18 t o 65 years.  The previous studies had study arms of similar size 
that proved to be sufficient to allow the collection of meaningful data, especially with respect to 
local and systemic reactogenicity symptoms and antibody levels.  
Though no hypothesis testing will be performed as part of the primary analyses, Table 2 and 
Table 3 show the probability of observing a safety event and statistical power to detect crossing 
a threshold in seroprotection rate, respectively, under a variety of hypothetical scenarios.  Within 
each table, separate calculations are performed for each pooled group of interest.   
Probabilities of detecting a safety event were calculated using the binomial distribution 
(Table 2) . 
Table 2: Probability of Observing at Least 1 Safety Event of Interest under Different 
True Event Rates  
True Probability of a 
Safety Event of Interest  Per Study 
Group (N=50)  Pooled Study 
Groups 
(N=100) Pooled ‚â•66 
Years of Age 
Cohort 
(N=200) Overall 
(N=300) 
0.0001 0.005 0.010  0.020  0.030  
0.005 0.222  0.394  0.633  0.778  
0.01 0.395  0.634  0.866  0.951  
0.02 0.636  0.867  0.982  0.998  
0.05 0.923  0.994  >0.999  >0.999 
0.1 0.995  >0.999  >0.999  >0.999 
A lower bound of 40% is considered to be a meaningful threshold of success for the 
seroprotection rate for BioThrax1.  Assuming a one-sided alpha level of 0.025, an exact 
binomial test was used to calculate the power to detect the lower bound of an exact 95% 
confidence interval (C I) about an observed seroprotection rate being ‚â•40%, using sample size 
and 
hypothetical true seroprotection rate scenarios shown in Table 3. 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  15  
   
    Table 3: Power for Detecting a Lower 95% Confidence Limit of ‚â•40% about an 
Observed Seroprotection Rate  
Hypothetical 
True 
Seroprotection 
Rate (%)  Per Study Group 
(N=50) Pooled Study 
Groups (N=100)  Pooled ‚â•66 Years 
of Age Cohort 
(N=200) Overall (N=300)  
50 0.240  0.460  0.782  0.926  
60 0.766  0.973  >0.999  >0.999  
70 0.988  >0.999  >0.999  >0.999  
80 >0.999  >0.999  >0.999  >0.999  
 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  16  
   
    5. STUDY DURATION AND V ISIT SCHEDULE  
Subjects will receive 3 study IP administrations , separated by approximately 14 days, and will be 
followed for 12 months after their last IP dose.  The expected study duration is approximately 
14 months per subject.  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  17  
   
    6. CLINICAL A SSESSMENTS  
6.1. Screening and Baseline Assessments  
Screening and baseline assessments include:  
1. Obtain  informed consent  
2. Inclusion/exclusion criteria assessment , including  the following:  
ÔÇ∑ urine p regnancy test  (for females)  
ÔÇ∑ urine drug screening  
ÔÇ∑ hemoglobin A1C (HbA1C)  >7.0%  
ÔÇ∑ human immunodeficiency virus (HIV), hepatit is B vaccine (HBV) and hepa titis C 
vaccine (HCV) screening  
3. Physical exam , including  vital signs assessment  
4. Medical history, medication use and immunization history (within 30 days of screening)  
5. Blood and urine sample s for clinical laboratory assessments (hematology, chemistry and 
urinalysis)  
6. Blood  samples  for baseline immunogenicity assessment parameters  
7. Autoantibody assay  
8. High-sensitivity C-reactive protein  (hs-CRP)  assay (for subjects ‚â•66 years of age)  
9. Electrocardiogram (EC G) 
6.2. Post-Baseline Assessments  
Post-baseline assessments include (not all are performed at each visit):  
1. Inclusion/exclusion criteria assessment for subsequent IP administrations, including urine 
pregnancy test for females  
2. Symptom -directe d physical exam, including vital signs assessment  
3. Changes in medication use  and immunization use  
4. Blood and urine sample s for clinical laboratory assessments (hematology, chemistry and 
urinalysis)  
5. Blood  samples  for post-baseline immunogenicity assessment pa rameters  
6. Autoantibody assay  
7. High -sensitivity C -reactive protein (hs -CRP) assay (for subjects ‚â•66 years of age)  
8. ECG 
9. AE/SAE/MAAE/PIMMC  assessment  
10. Diary dispensation and collection/review for AEs/SAEs/MAAEs/PIMMCs  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  18  
   
    11. Post-IP administration exam for local reactogenicity symptoms  and vital signs  
6.3. Final Evaluation or Early Termination Visit  
Final evaluation assessments at Visit 13 (Day 394) include:  
1. Changes in medication use and immunization use  
2. Blood for post -baseline immunogenicity assessment parameters  
3. ECG  
4. AE/SAE/MAAE/PIMMC assessment  
 
For subjects who discontinue study participation prior to Visit 10 (Day 64), an early termination 
visit will be performed. Assessment s that are conducted at early termination visits include:  
1. Symptom -directed  physical exam, in cluding vital signs assessment  
2. Changes in medication use and immunization use  
3. Blood and urine sample s for clinical laboratory assessments (hematology, chemistry and 
urinalysis)  if clinically indicated  
4. Blood  samples  for post -baseline immunogenicity assessment parameters  if within acceptable 
window for next expected study visit  
5. Autoantibody ass ay 
6. AE/SAE/MAAE/PIMMC assessment  
7. Diary collection/review for AEs/SAEs/MAAEs/PIMMCs  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  19  
   
    7. DEFINITIONS AND C ONVENTIONS  
 
7.1. General Summary  Table and Individual Subject Data Listing 
Considerations  
The following analyses and reporting conventions will be used:  
ÔÇ∑ Categorical variables will be summarized using counts (n) and percentages (%) and will 
be presented in the form ‚Äún (%).‚Äù  Percentages will be rounded to one decimal place.  If 
n=0, then no percent will be shown.  To ensure completeness, all summaries for 
categorical and discrete variables will include all categories, even if none of the subjects 
had a response in a particular category.  
ÔÇ∑ Numeric variables will be summarized using n, mean, standard deviation (SD), median, 
minimum (min), maximum (max).  The min /max will be reported at the same level of 
significance as original data.  The mean and median will be reported at one more 
significant digit than the precision of the data, and SD will be reported at two more 
significant digits than the precision of the d ata. 
ÔÇ∑ The median will be reported as the average of the two middle numbers if the dataset 
contains an even number of observations.  
ÔÇ∑ Test statistics including t, z and F test statistics will be reported to two decimal places.  
ÔÇ∑ P-values will be reported to thre e decimal places if greater than or equal to 0.001.  If less 
than 0.001, the value will be reported as ‚Äú<0.001.‚Äù  
ÔÇ∑ All tables, listings, and figures will be presented in landscape orientation.  
ÔÇ∑ Courier New 8-point  font will be used for all tables and listing s. 
ÔÇ∑ Dates will be displayed as ddmmmyyyy (e.g., 24Jan2017).  
If departures from these general conventions are present in the specific evaluations section of this 
SAP, then those conventions will take precedence o ver these general conventions.  
Tables, listi ngs, and figure s will include all study groups.  
Study groups will be presented in unblinded reports as shown below:  
ÔÇ∑ Study Group 1: Age ‚â•66 Arm 1  
ÔÇ∑ Study Group 2: Age ‚â•66 Arm 2  
ÔÇ∑ Study Group 3: Age ‚â•66 Arm 3  
ÔÇ∑ Study Group 4: Age ‚â•66 Arm 4  
ÔÇ∑ Study Group 5: Age 18 -50 Arm 1  
ÔÇ∑ Study Group 6: Age 18 -50 Arm 3  
Arms 1 through 4 will be defined in the footnotes of the displays.  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  20  
   
    7.1.1. Imputation of Missing Data  
There will be no methods of imputation used for missing data for the summaries or analyses of 
the primary and secondary endp oints.   No imputation will be implemented for safety  or 
immunogenicity  endpoint analys es.  
7.2. Calculations Using Dates  
Study days for dates on or after Visit 1 (Day 1) will be calculated as:  
ùëÜùë°ùë¢ùëëùë¶  ùê∑ùëéùë¶ =ùê∑ùëéùë°ùëí ‚àíùëâùëñùë†ùëñùë°  1 ùê∑ùëéùë°ùëí +1 
For dates prior to Visit 1 (Day 1), study days will be calculated as:  
ùëÜùë°ùë¢ùëëùë¶  ùê∑ùëéùë¶ =ùê∑ùëéùë°ùëí ‚àíùëâùëñùë†ùëñùë°  1 ùê∑ùëéùë°ùëí  
Total duration  is calculated as:  
ùê∑ùë¢ùëüùëéùë°ùëñùëúùëõ =ùê∏ùëõùëë  ùê∑ùëéùë°ùëí ‚àíùëÜùë°ùëéùëüùë°  ùê∑ùëéùë°ùëí +1 
Age (years) for randomized subjects at the time  of Visit 1 (Day 1) will be calculated as an integer 
according to the following formula:  
ùê¥ùëîùëí =ùêºùëõùë°ùëíùëîùëíùëü  ùëùùëúùëüùë°ùëñùëúùëõ  ùëúùëì  ùëâùëñùë†ùëñùë°  1 ùê∑ùëéùë°ùëí ‚àíùêµùëñùëüùë° ‚Ñé ùê∑ùëéùë°ùëí +1
365 .25 
Age for screen failures will be based on the informed consent date as oppo sed to Visit 1 (Day 1) 
date.  
7.3. Baseline 
For data collected at both Screening and Visit 1 (Day 1) pre -IP administration, the baseline  data 
will be defined as the latest non -missing value collected.  Otherwise, if data are collected at only 
one of Screening or  Visit 1 (Day 1), the collected value will be considered  the baseline  value for 
analyses . 
7.3.1. Visit Windows Relative to the First Dose of Study Medication  
The visit schedule and allowable visit windows are provided in Table  4.  Relative target days and 
visit windows are generally based on the timing of Visit 1 (Day 1).  Visits occurring within 
2 weeks of the 2nd or 3rd IP administration are show n with both relative target days and visit 
windows based on Visit 1 (Day 1) and relative target days and visit windows depending on the 
actual IP administration day (in parentheses).  Similarly, the Visit 13 relative target day and visit 
windows are based o n both Visit 1 (Day 1) and on the actual date of the 3rd IP administration.  
For these visits, if an applicable IP administration does not occur, the relative target day and visit 
window will be based on the date of the 1st IP administration at Visit 1 (Da y 1). 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  21  
   
    Table 4: Visit Schedule  
Visit Relative Target 
Day Visit Window  Modified 
Immunogenicity Per 
Protocol Population Visit 
Window 
Screening  Not Applicable  -14 ‚Äì -1 -14 ‚Äì -1 
Visit 1 (1st IP 
Administration ) 1 1 1 
Visit 2 (‚â•66 years of 
age only)  3 2 ‚Äì 4 2 ‚Äì 4 
Visit 3 8 8 ‚Äì 10 8 ‚Äì 10 
Visit 4 (2nd IP 
Administration ) 15  14 ‚Äì 18 12 ‚Äì 23 
Telephone Visit 1  17 (Visit 4 + 2)  16 ‚Äì 18 (Visit 4 + 2 ¬±1)  16 ‚Äì 18 (Visit 4 + 2 ¬±1)  
Visit 5 22 (Visit 4 + 7)  22 ‚Äì 24 (Visit 4 + 7 -0/+2)  22 ‚Äì 24 (Visit 4 + 7 -0/+2)  
Visit 6 (3rd IP 
Administration ) 29 (Visit 4 + 14)  28 ‚Äì 32 (Visit 4 + 14 -
1/+3)  26 ‚Äì 37 (Visit 4 + 14 -
3/+8)  
Telephone Visit 2  31 (Visit 6 + 2)  30 ‚Äì 32 (Visit 6 + 2 ¬±1)  30 ‚Äì 32 (Visit 6 + 2 ¬±1)  
Visit 7 36 (Visit 6 + 7)  36 ‚Äì 38 (Visit 6 + 7 -0/+2)  36 ‚Äì 38 (Visit 6 + 7 -0/+2)  
Visit 8 43 (Visit 6 + 14)  41 ‚Äì 44 (Visit 6 + 14 -
2/+1)  41 ‚Äì 44 (Visit 6 + 14 -
2/+1)  
Visit 9 50 48 ‚Äì 52 48 ‚Äì 52 
Visit 10 64 61 ‚Äì 67 61 ‚Äì 72 
Visit 11 85 82 ‚Äì 88 82 ‚Äì 88 
Visit 12 181 167 ‚Äì195  167 ‚Äì195  
Telephone Visit 3 366 359 ‚Äì373  359 ‚Äì373  
Visit 13 394 (Visit 6 + 365)  380 ‚Äì 408 (Visit 6 + 365 
¬±14)  380 ‚Äì 408 (Visit 6 + 365 
¬±14)  
 
Data from out -of-window visits will not be excluded from analyses.  
Unscheduled visits may also occur throughout the study.  Data from unscheduled visits will be 
included in listings but will generally not be included in tabular or graphical summaries.  The 
one exception is if the unscheduled visit occurs during the allowable visit window of a n expect ed 
study visit that is missed or where some or all immunogenicity data were not collected/not 
analyzable ; any available immunogenicity data from the unscheduled visit will be included in the 
summary of the expected study  visit. 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  22  
   
    Early termination visits may occur for any subject terminating the study prior to Visit 10 
(Day 64).  These visits will be summarized together in tabular summaries, and will be included 
in listings.  As with unscheduled visits, immunogenicity data from early termination visits that 
occur within the allowable visit window of an expected study  visit with some or all  
immunogenicity data missing  will be included in summaries of the expected study  visit.  
7.4. Analysis Populations  
7.4.1. Screen Failures  
A screen failure  is defined as any subject who  gives written informed consent but is not 
randomized  at Visit 1 (Day 1) .  In addition, all subjects who are screened and found eligible but 
are not randomized will be considered screen failures.  Besides reporting the reasons for not 
meeting inclusion/exc lusion criteria, screen failures will not be included in any other analyses.  
7.4.2. Randomized Population  
The randomized population will include all subjects who are randomized into the study, 
regardless of actually receiving an  IP dose. Each subject will be anal yzed as part of the study arm 
assigned/age group combination. If any subjects of age 18 -50 years are randomized in error to 
either arm 2 or arm 4  (due to randomization into the stratum for age ‚â•66 years) , those subjects 
will be included with the study group of subjects  age ‚â• 66 years  that corresponds to the 
randomized arm.  
7.4.3. Safety Population  
The safety population will include all subjects who are randomized and receive at least 1 IP dose.  
Each subject will be analyzed as part of the study group co rresponding to the actual study g roup 
for the applicable dose for individual dose summaries.  For all other analyses by study group, 
each subject will be analyzed corresponding to the actual study g roup for the first dose.  If any 
subjects of age 18 -50 yea rs are randomized in error to either arm 2 or arm 4  (due to 
randomization into the stratum for age ‚â•66 years) , those subjects will be included with the study 
group of subjects age ‚â•66 years that corresponds to the randomized arm. The safety population 
will be used for all safety analyses.  
7.4.4. Immunogenicity Full Analysis  Population  
The immunogenicity full analysis population (IFAP) will include all subjects who are 
randomized, receive d at least one IP dose, and have at least one determinate assay result at any 
post-vaccination  visit.  Each subject will be analyzed as part of the treatment and dosing 
schedule actually received, regardless of the treatment arm assignment.  If any subjects of age 
18-50 years are randomized in error to either arm 2 or arm 4  (due to randomization into the 
stratum for age ‚â•66 years) , those subjects will be included with the study group of subjects age 
‚â•66 years that corresponds to the randomized arm. The IFAP will be used only for analysis of 
seroprotection based on TNA NF 50 antibody l evels at Day 64 as a secondary analys is. 
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  23 7.4.5. Immunogenicity Per Protocol  Population  
The immunogenicity per protocol population (IPPP) will include all subjects who meet the 
following criteria:  
ÔÇ∑Randomized
ÔÇ∑Receive d a full dose of IP at Visit 1  (Day 1 ), Visit 4 ( Day 15 ), and  Visit 6  (Day 29 )
within protocol specified visit windows ( - 1 day, +3 days) (see Table  4).
ÔÇ∑Received the correct treatment as assigned by r andomization at Day 1, Day 15 and
Day 29.
ÔÇ∑Have no major protocol deviations that may have an impact on immunogenicity
assessments.  These are identified by a review of all protocol deviations by BARDA prior
to performing formal analyses and prior to data base lock .
ÔÇ∑Have Visit 10 (Day 64)  visit in-window (see Table 4) .
ÔÇ∑Have determinate assay results at the Day 64 visit.
The IPPP will be used for all primary and secondary immunogenicity endpoint assessments.   
7.4.6. Modified Immunogenicity Per Protocol Populatio n 
The modified immunogenicity per protocol population (MIPPP) will include all subjects who 
meet the following criteria  [note that the only differences between the following criteria and the 
IPPP criteria involve visit windows around vaccinations and Visit  10 (Day 64)]:  
ÔÇ∑Randomized
ÔÇ∑Received a full dose of IP at Visit 1 (Day 1), Visit 4 (Day 15), and Visit 6 (Day 29) 
within visit windows of 3 days before to 8 days after the expected visit date (see Table 4) .
ÔÇ∑Received the correct treatment as assigned by randomization at Day 1, Day 15 and
Day 29.
ÔÇ∑Have no major protocol deviations that may have an impact on immunogenicity
assessments.  These are identified b y a review of all protocol deviations by BARDA prior
to performing formal analyses and prior to database lock.
ÔÇ∑Have Visit 10 (Day 64) within a visit window of 3 days before to 8 days after the  
expected visit date (see Table 4).
ÔÇ∑Have determinate assay results at the Day 64 visit.
The MIPPP will be used to perform all primary and secondary immunogenicity endpoint 
assessments  as secondary analyse s. 
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  24 8. DATA PRESENTATIONS AND DAT A MANAGEMENT  
8.1. Data Presentations  
Tables, listings , and figures will be created to display  summary and subject  level  data.  
The plan for tabular presentations and analysis of the data, in general, is divided i nto three 
categories:  
1.Basel ine and demographic profile
2.Analyses of the primary, secondary and exploratory immunogenicity objectives
3.Safety and tolerability, including analyses of primary and secondary safety objectives
All datasets (Study Data Tabulation M odel [SDTM] and Analysis Data Model [ADaM] 
datasets), tables , and listings will be created using SAS software version 9.3 or higher.  Figures 
will be programmed using SAS or R version 3.4.1 or higher.  
8.2. Data Management  
Study centers will enter study data in an electronic data capture (EDC) system.  Laboratory data 
analyzed  by central laboratories (e.g. , chemistry, hematology, urinalysis and immunogenicity 
assays)  will be transferred to Rho and integrated into the SDTM datasets, but will not be 
included in the  EDC system.  
Refer to the Data Management Plan f or information concerning the EDC system . 
8.3. General Post Text Summary Table and Individual Subject Data 
Listing Format Considerations  
All tables and listings will be created using  RhoTables‚Ñ¢, a suite of  compiled  SAS macros  
created by Rho  for the generation of data displays .  For more information  on programming and 
validation processes, please see the Statistical Validation Plan.  
In general, each listing will be sorted by study group (sorted according to the order in Table 1), 
subjec t identification number (ID) and date.  For listings involving anoth er categorical variable 
(e.g. laboratory parameter), consideration will be m ade to group related results withi n each 
li
sting for ease of comparing data. 
Tables will include columns for each study group  (sorted according to the order in Table  1), by 
pooled age group (regardless of study group; i.e. separate summaries for 18 -50 years and 
‚â•66 years), by pooled study groups (regardless of age group) for arms 1 and 3,  and an overall 
column.  
Tables, listings , and figures will be numbered  and ordered  according to a decimal system 
consistent with the corresponding C SR section .  All displays will specify the applicable analysis 
population.  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  25  
   
    9. SUBJECT  ACCOUNTING AND DEMOGRAPHIC PROFILE OF 
SCREEN FAILURES  
9.1. Subject Accounting by Treatment Group and Sex 
The age, sex and race of screen failures will be included in the listing of eligibility criteria not 
met.  Since screen failures will not be randomized, no treatment group will be reported for these 
subjects.  
9.2. Subject Distribution by Site 
Screen failures will not be summarized by site.  
9.3. Screen Failures  
Subjects who sign informed consent and are screened but found to be ineligible will be 
considered to be screen f ailures.   In addition, all subjects who are screened and found eligible but 
are not randomized will be considered screen failures.   The specific eligibility  criteria not met 
will be listed for these subjects.  They will be excluded from other data displays.  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  26  
   
    10. SUBJECT DISPOSITION  
The study  disposition of all randomized  subjects will be summarized in tables and list ings. 
The numbers and percentages of subjects will be presented that meet the following criteria : 
‚Ä¢ Randomized  
‚Ä¢ Completed study 
‚Ä¢ Early termination from study  
In summary tables, p ercentages will be based on all  subjects random ized within the specific 
study group .  Categories  for early  study  termination reasons  will be presented , and percentages 
will be based on all subjects terminating early from the study within the specific study group . 
Visit completion will be presented in a  table as counts and percentages, reporting the status of 
the visit (completed or missed) and the number of subjects with visits out of window per visit.  A 
listing of subject visit completion status will be presented.  
The counts and percentages of subject s qualifying for each analysis population will be presented 
by study group.  Percentages will be based on all subjects randomized.   The primary reason for 
exclusion from the IPPP and the MIPPP will also be summarized as counts and percentages.   A 
listing o f each subject and analysis population inclusion will be presented.  
 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  27  
   
    11. BASELINE SUBJECT  DATA 
11.1. Baseline Demographic and Physical Characteristics  
Demographic and baseline  physical characteristics will be listed.  Summary statistics for 
demographic and baseline  physical  characteristics will be reported in tables for each analysis 
population.  Summaries by site will also be reported.  Demographic characteristics will be 
summarized based on data collected from the Screening visit and include age (years), race, 
ethnicity and sex. 
Body weight  (kg), height  (cm) and body mass index (BMI) (kg/ (m)2) will be reported from the 
Screening Visit , rounded to 1 decimal place .  If body weight is reported in pounds, the following 
formula will be used to convert to kg:  
ùêµùëúùëëùë¶  ùëäùëíùëñùëî‚Ñéùë° (ùëòùëî)=ùêµùëúùëëùë¶  ùëäùëíùëñùëî ‚Ñéùë° (ùëùùëúùë¢ùëõùëëùë† )
2.2 
 
If height is reported in inches, the following formula will be used to convert to cm:  
ùêªùëíùëñùëî ‚Ñéùë° (ùëêùëö)=ùêªùëíùëñùëî ‚Ñéùë° (ùëñùëõùëê‚Ñéùëíùë†)√ó2.54 
 
BMI will be calculated automatically within the EDC system using  the values of height and 
weight entered by clinical site staff, based on  the following formula :  
ùêµùëÄùêº =ùëäùëíùëñùëî ‚Ñéùë° (ùëòùëî)
(ùêªùëíùëñùëî ‚Ñéùë° [ùëö])2 
 
11.1.1. Listing of Subject Inclusion and Exclusion Criteria  
For subjects screened but found to be ineligible, specific inclusion criteria  not met and exclusion 
criteria  met will be listed.   Additional listings that show  specific inclusion criteria not met and 
exclusion criteria  met upon reassessment  prior to the 2nd or 3rd IP administration will also be 
produced.  
11.2. Medical History and Medical Conditions Present at Entry  
Medical history items will be coded according to a standardized thesaurus  (Medical Dictionary 
for Regulatory A ctivities [MedDRA] ; refer to the Data Safety Monitoring Plan ( DSMP ) for the 
applicable version ).  Frequencies and percentages of subjects with previous or current medical 
conditions or surgeries will be summarized by body system and study group.  Data listings will 
be prepared.  Potential body  systems assessed include  skin, HEENT (head, eyes, ears, nose and 
throat), respiratory, cardiovascular, gastrointestinal, endocrine/metabolic, genitourinary, 
neurological, blood/lymphatic, musculoskeletal, hepatic, allergies, and psychological/psychiatric.    
11.3. Prior Medication History and Medications Present at Entry  
Immunization history within 3 0 days prior to screening will be listed for all subjects, with 
vaccination type and date of vaccination.  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  28  
   
    Prior medication history will be summarized with concomitant  medication summaries.  
11.4. Screening  Laboratory Data  
HIV, HBV and HCV antibody  collection date and  results at screening will be listed for all 
subjects . 
HbA1C results at screening will be listed for all subjects, with date and time of collection, 
reference ran ges, abnormal flags and clinical significance indicators.  
Urine drug test results at screening will be listed for all subjects, with date of collection and 
results for each test.  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  29  
   
    12. IMMUNOGENICITY  
12.1. General Considerations  
All primary , secondary  and exploratory  immunogenicity analyses  will be performed on the IPPP  
and MIPPP separately , and the IFAP will be used only for the primary immunogenicity endpoint 
summaries  as a secondary analysis . 
Since all hypothesis tests are performed as part of the secondary analyses , all statistical 
inferences of immunogenicity endpoints are considered exploratory in nature, including 
unadjusted 95% CIs and unadjusted p-values as appropriate.  
No formal statistical analyses for the primary and secondary endpoints will be adjusted by s ite or 
any other covariates .  Exploratory analyses may use site as a covariate in models, in addition to 
other covariates that are deemed appropriate.  
12.2. Statement of the Null and Alternate Hypotheses  
There are no comparisons or hypotheses involved in the pri mary immunogenicity objective.  
As supportive analyses of the primary immunogenicity objective, the specified success criterion 
for TNA NF 50 antibody levels is that the 95% lower bound CI about the seroprotection rate 
(SPR) is greater than 40%.  The followi ng null hypothesis will be tested within each study group , 
combined age group,  combined treatment arm , and overall : 
1. Ho: SPR based on TNA NF 50 antibody levels at Day 64 is less than or equal to 40%  
Ha: SPR based on TNA NF 50 antibody levels at Day 64 is greater than 40%  
For secondary objectives comparing antibody levels in a pairwise fashion between  study  groups, 
the following null hypotheses will be tested for each pairwise  comparison at each timepoint 
where immunogenicity d ata are collected : 
1. Ho: SPR based on TNA NF 50 antibody levels in both groups are equal  
Ha: SPR based on TNA NF 50 antibody levels differ between groups  
2. Ho: seroconversion rate (SCR) based on TNA NF 50 antibody levels in both groups are 
equal  
Ha: SCR based on TNA NF 50 antibody levels differ between groups  
3. Ho: SCR based on TNA ED 50 antibody levels in both groups are equal  
Ha: SCR based on TNA ED 50 antibody levels differ between groups  
4. Ho: SCR based on ELISA anti -PA IgG antibody levels in both groups are equa l  
Ha: SCR based on ELISA anti -PA IgG antibody levels differ between groups  
5. Ho: TNA NF 50 antibody levels in both groups are equal  
Ha: TNA NF 50 antibody levels differ between groups  
6. Ho: TNA ED 50 antibody levels in both groups are equal  
Ha: TNA ED 50 antibo dy levels differ between groups  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  30  
   
    7. Ho: ELISA anti -PA IgG antibody levels in both groups are equal  
Ha: ELISA anti -PA IgG antibody levels differ between groups  
12.3. Subgroup Analyses  
No subgroup  analysis is planned . 
12.4. Multiple Comparisons and Multiplicity  
For all hyp othesis tests, significance will be declared at the two -sided Œ±=0.05 level.  Due to the 
exploratory nature of secondary analyses, no adjustments will be made for multiple comparisons.  
12.5. Analysis of the Primary Immunogenicity Endpoint  
The primary immunogenicity endpoint for this study is seroprotection at Day 64 based on TNA 
NF 50 antibody levels.  Seroprotection is defined as TNA NF 50 antibody ‚â•0.56.  
The primary analysis for this endpoint is descriptive.  The following summary statistics will be 
displayed:  
ÔÇ∑ count of subjects with non -missing data at the visit  
ÔÇ∑ count of subjects meeting criteria for seroprotection  
ÔÇ∑ proportion of subjects meeting criteria for seroprotection  
ÔÇ∑ 95% exact (Clopper -Pearson) CI corre sponding to the seroprotection rate  
In addition, SPRs and corresponding 95% CIs will be displayed graphically by study group on 
Day 64.  
The supportive analysis of the primary immunogenicity objective will be analyzed using a 
one-sided one-proportion z-test. 
P-values for the supportive analysis will be displayed.  
If more than 10% of subjects in the IPPP population are seroprotected at Visit 1 (Day 1) based on 
TNA NF 50 antibody levels, sensitivity analyses will be performed by repeating analyses 
described in this section excluding the subjects who are seroprotected at Visit 1 (Day 1).  
12.6. Analysis of the Secondary Immunogenicity Endpoints  
All secondary immunogenicity endpoints are listed below and will be analyzed according to 
Section  12.6.1.1  (antibody level endpoints)  or Section 12.6.1.2  (seroprotection and 
seroconversion endpoints) . 
ÔÇ∑ TNA NF 50 antibody levels at Days 1, 8, 22, 29, 36, 43, 50, 64, 85, 181 and 394  
ÔÇ∑ TNA ED 50 antibody levels at Days 1, 8, 22, 29, 36, 43, 50, 64, 85 , 181 and 394  
ÔÇ∑ ELISA anti -PA IgG antibody levels at Days 1, 8, 22, 29, 36, 43, 50, 64, 85, 181 and 394  
ÔÇ∑ Seroprotection based on TNA NF 50 antibody levels at Days 1, 8, 22, 29, 36, 43, 50, 85, 
181 and 394  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  31  
   
    ÔÇ∑ Seroconversion based on TNA NF 50 antibody levels at Day s 8, 22, 29, 36, 43, 50 , 64, 85, 
181 and 394, defined as a ‚â•4 -fold increase over baseline levels, or a ‚â•4 -fold increase over 
the LLOQ if the baseline value is below the LLOQ.  
ÔÇ∑ Seroconversion based on TNA ED 50 antibody levels at Days 8, 22, 29, 36, 43, 50 , 64, 85, 
181 and 394 , defined as a ‚â•4 -fold increase over baseline levels, or a ‚â•4 -fold increase over 
the LLOQ if the baseline value is below the LLOQ.  
ÔÇ∑ Seroconversion based on ELISA anti -PA IgG antibody levels at Days 8, 22, 29, 36, 43, 
50, 64, 85, 181 and 39 4, defined as a ‚â•4 -fold increase over baseline levels, or a ‚â•4 -fold 
increase over the LLOQ if the baseline value is below the LLOQ.  
 
12.6.1. Presentation of the Secondary Immunogenicity Results  
12.6.1.1. Antibody Levels  
Each secondary immunogenicity endpoint measuring TNA N F50, TNA ED 50 and ELISA anti -PA 
IgG antibody levels will be summarized similarly.   
Antibody levels with a value  that is less than LLOQ will be imputed for antibody level analyses 
as ¬Ω LLOQ . 
The following summary statistics will be displayed by visit as applicable:  
‚Ä¢ count of subjects with non -missing data at the visit  
‚Ä¢ geometric mean (GM) antibody levels and corresponding geometric standard deviation  
(SD)   
‚Ä¢ back -transformed 95% CI based on the t distribution about the GM antibody level  
‚Ä¢ minimum and maximum values  
‚Ä¢ median , and 1st and 3rd quartile values  
Study group summaries of GM antibody levels for TNA NF 50, TNA ED 50 and ELISA anti -PA 
IgG antibody levels by visit will be plotted on the log 10 scale with corresponding 95% CIs.  The 
reverse cumulativ e distributions of GM antibody levels for TNA NF 50, TNA ED 50 and ELISA 
anti-PA IgG antibodies at Visit 10 (Day 64) will also be plotted.  
Hypotheses concerning the immunogenicity antibody levels will be tested using pairwise t-tests 
on log 10 transformed ant ibody levels, and p-values, geometric mean ratios , and back -transformed 
95% CIs of the difference in log 10 antibody levels will be displayed.  
12.6.1.2. Seroprotection and Seroconversion Rates  
Each secondary immunogenicity endpoint involving seroprotection and seroco nversion rates will 
be summarized similarly.  The following summary statistics will be displayed by visit for each 
visit as applicable:  
ÔÇ∑ count of subjects with non -missing data at the visit  
ÔÇ∑ count of subjects meeting criteria for seroprotection or seroconve rsion  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  32  
   
    ÔÇ∑ proportion of subjects meeting criteria for seroprotection or seroconversion  
ÔÇ∑ 95% exact (Clopper -Pearson) CI corresponding to the seroprotection or seroconversion 
rate 
Hypothes es concerning the primary immunogenicity endpoint ( seroprotection rate at day 64) will 
be tested with a one -sample binomial test.  
Hypothes es concerning the comparison of SPR and SCR between different groups will be tested 
with a Fisher‚Äôs exact test  using the IPPP and MIPPP .  Risk differences of comparisons will be 
displayed with  corresponding 95% exact unconditional  CIs (based on the Santner and Snell 
method)  and p-values  (based on two -sided Fisher‚Äôs exact test) . 
A data listing of antibody levels will be prepared, which will include seroprotection (for TNA 
NF 50 antibody levels only) and seroconversion status (for TNA NF 50, TNA ED 50 and ELISA 
anti-PA IgG antibody levels separately) at each applicable visit.  
12.7. Analysis of the Exploratory Immunogenicity Endpoints  
12.7.1. Antibody level correlations  
Correlations between 1) TNA NF 50 and ELISA anti -PA IgG antibody levels and 2)  TNA ED 50 
and ELISA anti -PA IgG antibody levels will be calculated at Visit 10 (Day 64) .  Pairwise scatter 
plots  on the log 10 scale with regression lines will be created.  The Pearson correlation coefficie nt 
will be presented with corresponding p-value.  This analysis will be performed on the IPPP  and 
MIPPP . 
12.7.2. Additional pairwise comparisons  
The following pairwise  comparisons  of TNA NF 50 antibody levels  and seroprotection rates  will 
be performed at the given visit using the hypothesis testing methodology stated  in Section  
12.6.1.1 : 
1. Group  1 vs. combined Group s 2 and 3 at Day 29  
2. Group  1 vs. Group 3 at Day 64  
3. Group  1 vs. Group 4 at Day 64  
4. Group 5 vs. Group 6 at Day 29 
5. Group  5 vs. Group 6  at Day 64  
The hypotheses applicable to each pairwise comparison are the following:  
Ho: TNA NF 50 antibody levels  (or seroprotection rates)  in both groups are equal  
Ha: TNA NF 50 antibody levels  (or seroprotection rates)  differ between groups  
These analyse s will be performed on the IPPP  and MIPPP  by the treatment actually received.  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  33  
   
    13. SAFETY AND T OLERABILITY  
13.1. Overall Summary of Tolerability  
Only treatment -emergent AEs, those starting or worsening in severity on or after the first IP 
administration, are collected on the eCRF.  AEs with missing start dates will be considered 
treatment -emergent.  
All safety analyses will be carried out using the safety population defined in Section 3.1 unless 
otherwise noted.  Missing safety information will not be imputed.  These analyses will not be 
stratified by site or sex.   
The following summaries of all AEs will be given for combined dose 1, dose 2 and dose 3, as 
well as individually for dose 1, dose 2 and dose 3:  
ÔÇ∑ AEs by SOC and PT  
ÔÇ∑ AEs by AE Type (Solicited  or Unsolicited) and PT  
ÔÇ∑ AEs by SOC, PT and maximum severity  
ÔÇ∑ AEs by SOC, PT and relationship to IP  
ÔÇ∑ AEs by SOC, PT and earliest days of onset  
ÔÇ∑ The count of AEs and percentage of subjects experienci ng AEs that fit the following 
categories:  
o AEs (overall and related to IP)  
o SAEs  (overall and related to IP)  
o Severe AEs  (overall and related to IP)  
o AEs leading to early termination of IP  
o AEs leading to study withdrawal  
o AEs leading to death  
o Solicited local reactogenicity symptoms (overall and severe)  
o Solicited local contralateral reactogenicity symptoms (overall and severe)  
o Solicited systemic reactogenicity symptoms (overall and severe)  
o PIMMCs  (overall and severe)  
o MAAEs  (overall and severe)  
o Unsolicited AEs  (overall and severe)  
13.2. Adverse Event Preferred Term and System Organ Class  Summary 
Tables 
All AEs will be classified by system organ class (SOC) and preferred term (PT), according to 
MedDRA .  For solicited reactogenicity symptoms of injection site tenderness,  the low level term 
will be used instead of preferred term to distinguish these symptoms from injection site pain, as 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  34  
   
    they are explicitly collected in subject diaries and vaccine  site examinations.   The severity and 
attribution of AEs will be classified by  the investigator on the eCRF.  Each AE is entered on the 
eCRF once at the highest severity.  
13.2.1. Summaries of Adverse Event Incidence Rates for All Subjects 
Separate summaries of solicited local and systemic reactogenicity  symptoms and unsolicited AEs 
will be prepared for  the following:  
ÔÇ∑ combined dose 1, dose 2 and dose 3 (start dates occurring in the periods of Day 1 through 
8, Day 15 through Day 22, and Day 29 through 36)  
ÔÇ∑ dose 1 only (start dates occurring in the period of  Day 1 through 8)  
ÔÇ∑ dose 2 only (start dates occurring in the p eriod of Day 15 through 22)  
ÔÇ∑ dose 3 only (start dates occurring in t he period of Day 29 through 36)  
AEs beginning after  the 1st IP administration on Day 1 and prior to the 2nd IP administration on  
Day 15 will be included in dose 1 summaries.   AEs that begin prior to the 1st IP administration 
will only be included in dose 1 summaries if they worsen after IP administration.   Similarly, AEs 
that start after the 2nd IP administration on Day 15 and prio r to the 3rd IP administration will be 
included in dose 2 summaries.  AEs beginning after the 3rd IP administration on Day 29 and prior 
to or on Day 50 will be included in dose 3 summaries.  
For summaries  of AEs, the count of events that fit the specified c riteria will be presented.   
The number of subjects experiencing at least one event will be described using counts and 
percentages per study group.  Percentages will be based on the number of subjects in the safety 
population within the study group.  For s ummaries of events associated with dose 2 or dose 3, 
percentages will be based on the number of subjects in the safety population within the study 
group who received the 2nd or 3rd IP administration, respectively.  
The incidence of AEs will be summarized . If a subject experienced more than one episode of an 
AE, the subject is counted once for that PT. If a subject had more than one AE in a SOC (or AE 
type, if applicable), the subject is counted only once in that SOC (or AE type)  according to the 
highest seve rity rating (in order, mild  [grade 1] , moderate  [grade 2] , or severe  [grades 3, 4 and 
5]).  If the severity of the AE is not reported, then the severity of the AE will be counted as 
unknown.   The summary tables will include incidence estimates for overall SOC (or AE type) as 
well as for PTs within each SOC (or AE type).  Incidence will be presented  alphabetically  by 
SOC (or AE type) and then by PT within each SOC (or AE type) by decreasing frequency 
overall and then alphabetically.  
The investigator is to re cord their opinion on the relationship of each AE to IP ( ‚Äúnot related ‚Äù, 
‚Äúunlikely related ‚Äù, ‚Äúpossibly related ‚Äù, ‚Äúprobably related ‚Äù and ‚Äúrelated ‚Äù).  If a subject experiences 
the same AE multiple times, the event with the strongest relationship to IP will be counted.  For 
summaries of IP -related AEs, the categories of ‚Äúpossibly related ‚Äù, ‚Äúprobably related ‚Äù and 
‚Äúrelated ‚Äù will be considered IP -related.  I f the relationship is missing, it will be counted as 
‚Äúrelated ‚Äù in summaries.  
Day of onset relative to the most recent IP administration will be dichotomized for summaries as 
‚â§8 days  post IP administration and ‚â•9 days post IP administration.  If a subject experiences the 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  35  
   
    same AE multiple times  for the same IP administration , the event with the closest start date to IP 
administration will be counted.  
Solicited local reactogenicity symp toms and solicited systemic reactogenicity symptoms will be 
summarized by maximum severity with 95% exact ( Clopper -Pearson) CIs for dose 1, dose 2 , and 
dose 3 , separately, and combined dose 1 , dose  2 and dose 3 .  Solicited local reactogenicity 
symptoms on the contralateral arm will be summarized similarly for dose 2 and dose 3.  
In addition, solicited systemic reactogenicity symptoms will be summarized by the strongest 
relationship to IP in the same method as described above.  
Unsolicited adverse events will be summarized by maximum severity with 95% exact (Clopper -
Pearson) CIs for dose 1, dose 2 , and dose 3, separately, and combined dose 1, dose 2 , and dose 3.  
In addition, all AEs will be listed  by subject  in chronological order including ID, age, race, sex, 
and all related event status information (start and stop dates, whether the event was resolved , 
study day of onset, severity, seriousness, relationship to IP, action taken with IP, and outcome). 
Separate flags will be displayed for solicited local reactoge nicity symptoms, solicited systemic 
reactogenicity symptoms, SAEs, PIMMCs, MAAEs, unsolicited AEs, deaths, AEs leading to 
treatment discontinuation, and AEs leading to subject study withdrawal.  Additionally, a coding 
list of PTs and the verbatim text asso ciated with them will be produced.  
SAEs, MAAEs and PIMMCs will be summarized  in tables  and presented in separate listings . 
13.2.2. Missing and Partial AE Onset Dates  
The following conventions will be used for imputing missing start dates.  
ÔÇ∑ For start dates that are missing the day value with non -missing month and year:  
o If the start year is the same as the year of Visit 1 (Day 1), then do the following:  
ÔÇß If the start month is the same as the month of Visit 1 (Day 1), the start date 
will be imputed as the date of Visit 1 (Day 1).  
ÔÇß If the start month is not the same as the month of Visit 1 (Day 1), then the 
start date will be imputed as the first day of the non -missing start month.  
o If the start year is not the same as the year of Visit 1 (Day 1), then the start day 
will be  imputed as the first day of the start month.  
ÔÇ∑ For start dates that are missing the day and month values with non -missing year:  
o If the start year is the same as the year of Visit 1 (Day 1), the start date will be 
imputed as the date of Visit 1 (Day 1).  
o If the start year is after the year of Visit 1 (Day 1), the start month and start day 
will be imputed as January 1.  
ÔÇ∑ Completely missing start dates will be imputed as the date of Visit 1 (Day 1).   
End dates will not be imputed.  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  36  
   
    13.2.3. Early Termination of Investigational Product due to Adverse Event, Subject 
Study Withdrawal due to Adverse E vent, and Death  
AEs leading to early termination of IP will be summarized in a table by SOC and PT  and will be 
presented in listings .  Similar summa ries and listings will be provided for AEs leading to subject 
study withdrawal . AEs leading to d eath and potentially life-threatening (grade 4) AEs will also 
be listed . 
13.3. Pregnancy Monitoring and Assessment  
Urine pregnancy assessments will be done at Screeni ng and prior to IP administration on Visit 1 
(Day 1), Visit 4 (Day 15) and Visit 6 (Day 2 9).  Date, time and result of each pregnancy 
assessment will be listed for all female subjects . 
In the case of one or more pregnancies occurring during study participa tion, a data listing will be 
prepared to display applicable information, including date of report, method of pregnancy 
confirmation, delivery date (if applicable), pregnancy termination status and week (if applicable), 
and any problems or congenital abnorm alities present.  
13.4. Safety Endpoint Analyses  
13.4.1. General Considerations  
All statistical inferences of safety endpoints are considered exploratory in nature, including 
unadjusted 95% CIs. 
13.4.2. Statement of the Null and Alternate Hypotheses  
There are no comparisons or hypotheses involved in the primary  or secondary  safety  objective s. 
13.4.3. Subgroup Analyses  
No subgroups will be analyzed.   No by -site analyses are planned.  
13.4.4. Analysis of the Primary Safety Endpoint  
The primary safety endpoint for the study is all solicited local a nd systemic reactogenicity 
symptoms occurring within 8 days of each IP administration, inclusive of the IP administration 
day, excluding reactogenicity symptoms on the contralateral arm . 
For the primary safety endpoint, a solicited local or systemic reacto genicity symptom is defined 
as any of the following occurring within 8 days after each IP administration, inclusive of the IP 
administration day, excluding reactogenicity symptoms on the contralateral arm : 
ÔÇ∑ Solicited local reactions at the injection site: w armth, tenderness, itching, pain, restriction 
of range of arm motion, erythema/redness, palpable or observable lump, 
induration/swelling, and bruising  
ÔÇ∑ Solicited systemic reactions: fatigue, myalgia/muscle ache, headache, and fever  
Primary endpoint results will be summarized with frequency, percentage and 95% confidence 
interval, and displayed i n tables described in Section 13.2.1 . 
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  37 13.4.5. Analysis of the Secondary Safety Endpoints  
All secondary saf ety endpoints are listed below:  
ÔÇ∑All treatment -emergent unsolicited A Es. Unsolicited AEs are defined as all other than
solicited local and systemic reactogenicity symptoms .
ÔÇ∑All treatment -emergent SAEs occurrin g during study participation.  SAEs are defined in
Protocol Section 11.2.1.3.
ÔÇ∑All treatment -emergent MAAEs occurring during study participation.  MAAEs are
defined as AEs with medically attended visits including hospital, emergency room,
urgent care clinic , or other visits to or from medical personnel for any reason.   AEs (e.g.
abnormal vitals) identified at a routine study visit will not be considered MAAEs.
ÔÇ∑All treatment -emergent PIMMCs that occur during study participation.  PIMMCs are
defined in Protoco l Appendix 3 .
ÔÇ∑All solicited local reactogenicity symptoms on the contralateral arm occurring within
8 days after each vaccination, inclusive of the vaccination day .
Secondary  endpoint results will be summarized with frequency and percentage, and displayed  in 
tables described in Section  13.2.1 . 
13.4.6. Summary of Reasons for Safety Non-evaluability/Exclusion from Safety 
Analyses  
All subjects who are randomized and receive at least 1 IP administration will be included in 
safety analyses.  Therefore, a listing of screen failures will be considered the presentation of 
subjects excluded from safety analyses.  
13.5. Investigational Product Administration  Compliance  
IP administr ation adherence for dose 1 at Visit 1(Day 1), dose 2 at Visit 4 (Day 15) and dose 3 at 
Visit 6 (Day 29) will be summarized and listed.  Counts and percentages of subjects receiving 
any amount or a full amount of dose 1, dose 2 and dose 3, separately, will be reported in tables; 
the denominator will be the number of subjects within each group as randomized.  For subjects 
who receive all 3 doses of IP, the counts and percentages of subjects receiving 3 doses of IP 
according to the correct study arm will be su mmarized.  For subjects terminating IP 
administration early, the reasons for terminating IP administration early will also be presented.  
For subjects who received the first IP administration but are found ineligible for the second or 
third IP administrati on, specific inclusion and exclusion criteria not met at Visit 4 (Day 15) or 
Visit 6 (Day 29) will be listed separately.  
Details of IP administration will be listed for each IP administration, including date of IP 
administration, time IP removed from stora ge/refrigerator, time of IP preparation, time of 
administration, location of administration and whether a full dose was received.  
13.6. Concomitant and Other Medications  
Medications will be coded according to the World Health Organization (WHO) Drug Dictionary 
(refer to the DSMP for the applicable version ).  Medications reported on the eCRF will be 
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  38 categorized for analysis as prior or concomitant to IP administration by comparing the 
medication start and stop dates with the first IP administration dates.  Prior m edications will have 
a medication start date prior to the first IP administration date.  Concomitant medications will 
have a medication start on or after the first IP administration date or a stop date on or after the 
first IP administration date.  Medicat ions that fit the criteria for both a prior and concomitant 
medication will be indicated as such in data listings.  
The number and percentage of subjects receiving prior or concomitant medications will be 
presented overall and by medication class.  When rep orting the number of subjects receiving the 
medication, a subject will only be counted once if they ever received the medication within the 
medication class.  
Medication usage will be listed, including Anatomical Therapeutic Chemical (ATC) level 4 
coding te rm, verbatim drug name, preferred drug name, start date, end date, dose (with unit), 
frequency, route, ongoing status and indication . 
Non-IP immunizations will be collected post -Screening.  Concomitant immunizations will be 
listed, including immunization t ype and date.  
13.6.1. Missing and Partial Concomitant and Other Medication Start and Stop Dates  
The following conventions will be used for imputing missing start dates.  
ÔÇ∑For start dates that are missing the day value with non -missing month and year:
oIf the start year is the same as the year of Visit 1 (Day 1), then do the following:
ÔÇßIf the start month is the same as the month of Visit 1 (Day 1), the start date
will be imputed as the date of Visit 1 (Day 1).
ÔÇßIf the start month is not the same as the month of Visit 1 (Day 1), then the
start date will be imputed as the first day of the non -missing start month.
oIf the start year is not the same as the year of Visit 1 (Day 1), then the start day
will be imputed as the first day of the non -missing start month.
ÔÇ∑For start  dates that are missing the day and month values with non -missing year:
oIf the start year is earlier than the year of Visit 1 (Day 1), the start month and day
will be imputed as July 1.
oIf the start year is the same as the year of Visit 1 (Day 1), the star t date will be set
to the date of Visit 1 (Day 1).
oIf the start year is after the year of Visit 1 (Day 1), the start month and start day
will be imputed as January 1.
ÔÇ∑Completely missing start dates will be imputed as the date of Visit 1 (Day 1).
End dates  will not be imputed.  
13.7. Investigational Product Administration Site Examination  
Observations from the IP administration site post IP administration will be summarized by visit 
and study group.  IP administration site examinations will be summarized separately for 
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  39 locations of dose 1, dose 2 and dose 3.  Dose 1 site examinations will occur on Visit 1(Day 1), 
Visit 2 (Day 3) (for ‚â•66 age group), Visit 3 (Day 8) and Visit 4 (Day 15); dose 2 site 
examinations will occ ur on Visit 4 (Day 15), Visit 5 (Day 22) and Visit 6 (Day 29); dose 3 site 
examinations will occur on Visit 6 (Day 29), Visit 7 (Day 36) and Visit 8 (Day 43).  Counts and 
percentages of subjects experiencing warmth, tenderness, itching, pain, restriction o f range of 
arm motion, erythema/redness, palpable or observable lump, induration/swelling, and bruising at 
the injection site will be presented.  Summaries of the largest diameter of erythema/redness , and 
induration/swelling will be presented as well.  
IP administration site examination information will also be listed for each subject, dose and visit.  
Information included will be IP administration date, date of examination, time of examination, 
days since IP administration, whether a photograph was taken of  the abnormality, and all 
information summarized in IP administration site examination tables described above in this 
section.  
13.8.  Diary Card Measurements  
Participant -reported diary card measurements of vaccinated and contralateral arm (if applicable) 
IP admi nistration site erythema/redness and induration/swelling will be listed for each subject, 
dose and study day for 8 days post -IP administration.  
13.9. Clinical Laboratory Data  
Clinical  laboratory measurements of serum chemistry, hematology and urinalysis will be 
performed at a central laboratory.  All clinical laboratory data will be reported using the 
International System of Units (SI).  If SI units are not available, laboratory -reported units will be 
used.  Descriptive statistics of laboratory values will be pre sented  by visit .  Summaries of actual 
values and change from baseline values by visit will be presented for quantitative laboratory 
parameters (e.g., white blood cells , lymphocytes).   Baseline is defined as the last lab value prior 
to IP administration.  
If two or more evaluations occur in the same visit window, the latest evaluation will be selected 
for inclusion in the analysis.   
Clinical laboratory results will receive a toxicity grade according to Protocol Appendix 2 .  
Clinical laboratory results  of gra de 1 through 3  that are deemed by the investigator as being 
clinically significant will be recorded as AEs with a corresponding toxicity grade as described 
above and will be presented with the AE displays.   All grade 4 laboratory values will be 
considered AEs.   
Shift tables will be prepared to display cross -tabulations of the number of subjects experiencing 
each toxicity grade at baseline compared to other visits by clinical laboratory test.  
All clinical laboratory values will be presented in a listing.  
13.10. Vital Signs 
Vital signs parameters of blood pressure (systolic and diastolic) (mmHg), pulse rate 
(beats/minute), re spiratory rate (breaths/minute), oral temperature (¬∞F) , and oxygen saturation by 
pulse oximeter (%)  will be summarized and listed for all visit s with applicable data.  For all 
HHS/ASPR/ BARDA  BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0  11 April 2019  
CONFIDENTIAL AND PROPRIETARY  40 results collected post -baseline , change from baseline will be displayed.  Visit 1 (Day 1) pre -IP 
administration vital signs results will be considered baseline for summaries of vital signs data.  If 
the Visit 1 (Day 1) pre -IP administration result is missing, screening results will be considered 
baseline.  
Toxicity grading of vital signs results according to  Protocol Appendix  2 will be presented with 
vital signs displays.  Vital signs results that are deemed by the investigat or as being clinically 
significant will be recorded as AEs with a corresponding toxicity grade as described above and 
will be presented with the AE displays.   
Shift tables will be prepared to display cross -tabulations of the number of subjects experiencin g 
each toxicity grade at baseline compared to other visits by vital sign parameter.  
All vital signs will be listed in by -subject listings including visit and collection date.  
13.11. Physical Examination  
Physical examination s will be performed, but only abnormal r esults will be recorded as either a 
medical history item at screening, or as an adverse event.  Physical exam results will not be 
reported otherwise.  
13.12. Other Safety Assessments  
ECG test results will be collected at Screening, Visit  7 (Day 36) and Visit 13 (Day 394).  Results 
will be reported in data listings, including visit and collection date.  
High -sensitivity C -reactive protein  (hs-CRP ) assay results will be collected at Visit 1 (Day 1) 
and Visit 2 (Day 3) for subjects ‚â•66 years of age.  Results will be reported in data listings, 
including visit and collection date.  
Blood samples for a utoantibody assays  will be collected  and frozen  for potential testing  at Visit 1 
(Day 1), Visit 10 (Day 64) and at the early termination visit (if a pplicable) for subjects ‚â•66 years 
of age.  If the samples are analyzed, r esults will be reported in data listings, including visit and 
collection date.  
13.13. Subject Study Withdrawal  Status 
Reasons for  subject  study withdrawal  will be included in the study disp osition displays described 
in Section 10. 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  41  
   
    14. PROTOCOL DEVIATIONS  
Protocol deviations captured in the eCRF, including site -level protocol deviations, will be listed 
by site with information such as type of deviation, severity of the deviation (major or 
non-major), date of occurrence, and the reason for the deviation.  Protocol deviations will be 
summarized in tabular format by type of deviation.  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  42  
   
    15. MAINTAINING THE BLIND 
For all analyses requiring unblinded data from study start through the Day 394 analysis for the 
final CSR, a blinded programming team consisting of programmers and statisticians will perform 
all programming tasks (including SDTM datasets, ADaM  datasets, ta bles, listings , and figures) 
and all associated validation tasks using dummy study groups, which will be randomly assigned.  
After validation of datasets and displays using dummy study groups, an unblinded team of a 
statistician and a programmer will gener ate, interpret and report each analysis using appropriate 
study groups and will not modify any programs used to perform analyses.   
Any necessary modification of programs due to incorrect coding will be communicated from the 
unblinded team to the blinded t eam so that the blinded team can modify the coding while being 
blinded to study groups, after which the unblinded team will then rerun analyses using unblinded 
data.  This process is continued until the unblinded team ensures all data issues have been 
resolved.  
15.1. Immunogenicity Data  
Immunogenicity data of TNA NF 50, TNA ED 50 and ELISA anti -PA IgG antibody levels may 
potentially be unblinding to study group, as a higher antibody level would be expected from 
subjects receiving active IP compared to placebo.  To ensure that no blinded individual may be 
unblinded by viewing the immunogenicity data, the unblinded statistician will randomly reassign 
the IDs in the file so that antibody levels will be assigned to different subjects than those subjects 
to which they ac tually correspond.  Blinded programming tasks will be done only on the 
reassigned file.  The file with correct ID assignments will be used for all unblinded analyses and 
will only be viewable by unblinded individuals.  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  43  
   
    16. INTERIM ANALYSES  
An interim analysis w ill be performed based on cumulative immunogenicity and safety data 
through Visit 10 (Day 64) for all subjects.   At the interim analysis, the study database (all data 
through Visit 10 [Day 64]) will be monitored and cleaned per the Data Management Plan.  
The blinding at the subject level will be maintained for those outside of the unblinded team until 
database lock of all data through Day 394 for the clinical study report.  Blinding  at the subject 
level  will be maintained for the interim analysis as specifi ed in Section 15. 
All primary and secondary endpoint analyses will be performed for the interim analysis as 
specified in Section s 12.6 and 12.7 (for immunogenicity analyses) and Sections 13.4.4  and 
13.4.5  (for safety analyses) .  Additional analyses included in the interim analysi s, such as subject 
disposition and demographics, will be performed based on Sections  10 and 11.  Exploratory 
immunogenicity analyses will also be included in the interim analysis.  
In order to prevent unblinding of any individual subjects, tabular summaries of data will exclude 
extreme v alues (minimum and maximum).  Listings will not be included in the interim analysis 
package.  Immunogenicity tables and figures will report study group and pooled group statistics 
and counts. AE  tables will not report study group specific counts, but will i nstead report the 
overall totals and totals by age group.  As such AE tables will remain blinded, even at the group 
level. All remaining tables included in the interim analysis that may have small counts will not 
report study group specific counts for appli cable variables.    
The unblinded statistician will be responsible for reporting interim results to  Biomedical 
Advanced Research and Development Authority  (BARDA ). 
Since all active subjects will have completed Visit 10 (Day 64) and this timepoint is of prim ary 
interest , there will be no penalty for an early look at the data.  In addition, no decisions regarding 
the status of the study will be made as a result of the interim analysis.  
The interim analysis tables and figures will be a subset of the final table s and figures included in 
the CSR. At the time of the final analysis  for the CSR , all tables  and figures generated as part of  
the interim analysis will be regenerated to include da ta through the end of the study.  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  44  
   
    17. SAFETY MONITORING COMMITTEE MEETINGS  
The Safety Monitoring Committee (SMC) will perform a planned review of interim safety data 
after 40 subjects ‚â•66 years of age have completed Visit 7 (Day 36).  Enrollment and dosing will 
continue during this planned SMC review.  In addition, ad hoc reviews wil l occur in the event 
that pausing/stopping rules are met or a review is deem ed necessary by the SMC chair.  
Following the planned interim analysis (described in Section 16), a final set of SMC data 
displays will be  provided to the SMC members.   These displays will be of the same format as 
provided for the planned SMC data review but will be run on the clean and frozen data from the 
interim analysis . 
The bl ind will be maintained for all blinded individuals according to Section 15.  The unblinded 
statistician will be responsible for presenting data to the SMC.  Safety analyses for SMC review 
will be completed using the safety population.   
Refer to the SMC Charter for more details of the SMC procedures and reporting.  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  45  
   
    18. CHANGES TO COMPLETED REPORTS  
The study database will be monitored and cleaned per the Data Management Plan for all data 
through Visit 10 (Day 64) for the interim analysis and Visit 13 (Day 394) for the final CSR.  In 
the event of any change s in the clinical database  at the time of final database lock that affect  
information reported in the interim analysis , these changes will be noted in the CSR.  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  46  
   
    19. REFERENCES  
1. BioThrax¬Æ (Anthrax Vaccine Adsorbed); Suspension for Intramuscular or Subcutaneous 
Injection [package insert]. Lansing, MI: Emergent BioDefense Operations Lansing LLC, 
2015.  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  47  
   
    20. APPENDIX  
20.1. Table of Contents for Data Display Specifications  
Tables  
Table 
Number Table Title  Applicable 
Reports 
(I=Interim,  
C=Final 
CSR) Applicable 
Populations 
(R=Randomized, 
S=Safety,  
F=IFAP,     
P=IPPP 
M=MIPPP ) 
Table 
14.1.1.1  Subject Disposition  by Study Group  I, C R 
Table 
14.1.1.2  Visit Completion  by Study Group  I, C R 
Table 
14.1.1.3  Analysis Populations by Study Group  I, C R 
Table 
14.1.2  Protocol Deviations  by Study Group  C R 
Table 
14.1.3.1  Demographics and Baseline Physical 
Characteristics  by Study Group  I, C S, F, P , M 
Table 
14.1.3.2  Demographics and Baseline Physical 
Characteristics by Site  and Study Group  C S, F, P , M 
Table 
14.1.4  Medical History  by Study Group  C S 
Table 
14.1.5  Concomitant Medications  by System Organ 
Class, Preferred Term and Study Group  C S 
Table 
14.1.6  Investigation al Product Administration 
Adherence  by Study Group  I, C S 
Table 
14.2.1.1  Seroprotection by TNA NF 50 Antibody Levels 
Summary  by Study Group   I, C F, P, M 
Table 
14.2.1.2  Exploratory Seroprotection by TNA NF 50 
Antibody Levels Summ ary Comparisons  I, C P, M  
Table 
14.2.1. 3 TNA NF 50 Antibody Levels Summary  by 
Study Group   I, C P, M 
Table 
14.2.1.4  Exploratory TNA NF 50 Antibody Level 
Summary Comparisons  I, C P, M  
Table 
14.2.1. 5 Seroconversion by TNA NF 50 Antibody 
Levels Summary by Study Group   I, C P, M  
Table 
14.2.2.1  Seroconversion by TNA ED 50 Antibody 
Levels Summary by Study Group   I, C P, M  
Table 
14.2.2.2  TNA ED 50 Antibody Levels Summary by 
Study Group   I, C P, M  
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  48  
   
    Table 
14.2.3.1  Seroconversion by  ELISA anti -PA IgG  
Antibody Levels Summary by Study Group   I, C P, M  
Table 
14.2.3.2  ELISA anti -PA IgG  Antibody Levels 
Summary by Study Group   I, C P, M  
Table 
14.3.1.1.1  Summary of Adverse Events by Study Group  I, C S 
Table 
14.3.1.1.2  Summary of Adverse  Events for Dose 1 by 
Study Group  I, C S 
Table 
14.3.1.1.3  Summary of Adverse Events for Dose 2 by 
Study Group  I, C S 
Table 
14.3.1.1.4  Summary of Adverse Events for Dose 3 by 
Study Group  I, C S 
Table 
14.3.1.1.5  Summary of Adverse Events  by Study Group  
and Dose  I, C S 
Table 
14.3.1.2.1  All Adverse Events by System Organ Class, 
Preferred Term and Study Group  I, C S 
Table 
14.3.1.2.2  All Adverse Events by System Organ Class, 
Preferred Term and Study Group for Dose 1  I, C S 
Table 
14.3.1.2.3  All Adverse Events by System Organ Class, 
Preferred Term and Study Group for Dose 2  I, C S 
Table 
14.3.1.2.4  All Adverse Events by System Organ Class, 
Preferred Term and Study Group for Dose 3  I, C S 
Table 
14.3.1.2. 5 All Adverse Events by System Organ Class, 
Preferre d Term , Study Group and Dose  I, C S 
Table 
14.3.1.3.1  All Adverse Events by Type, Preferred Term 
and Study Group  I, C S 
Table 
14.3.1.3.2  All Adverse Events by Type, Preferred Term 
and Study Group for Dose 1  I, C S 
Table 
14.3.1.3.3  All Adverse Events by Type, Preferred Term 
and Study Group for Dose 2  I, C S 
Table 
14.3.1.3.4  All Adverse Events by Type, Preferred Term 
and Study Group for Dose 3  I, C S 
Table 
14.3.1.4.1  All Adverse Events by System Organ Class, 
Preferred Term, Maximum Severity and Study 
Group  I, C S 
Table 
14.3.1.4.2  All Adverse Events by System Organ Class, 
Preferred Term, Maximum Severity and Study 
Group for Dose 1  I, C S 
Table 
14.3.1.4.3  All Adverse Events by System Organ Class, 
Preferred Term, Maximum Severity Study 
Group for Dose 2  I, C S 
Table 
14.3.1.4.4  All Adverse Events by System Organ Class, 
Preferred Term, Maximum Severity and Study 
Group for Dose 3  I, C S 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  49  
   
    Table 
14.3.1.5.1  All Adverse Events by System Organ Class, 
Preferred Term, Strongest Relationship to 
Investigational Product and Study Group  I, C S 
Table 
14.3.1.5.2  All Adverse Events by System Organ Class, 
Preferred Term, Strongest Relationship to 
Investigational Product and Study Group for 
Dose 1  I, C S 
Table 
14.3.1.5.3  All Adverse Events by System Organ Class, 
Prefe rred Term, Strongest Relationship to 
Investigational Product and Study Group for 
Dose 2  I, C S 
Table 
14.3.1.5.4  All Adverse Events by System Organ Class, 
Preferred Term, Strongest Relationship to 
Investigational Product and Study Group for 
Dose 3  I, C S 
Table 
14.3.1.6.1  All Adverse Events by System Organ Class, 
Preferred Term, Earliest Day of Onset and 
Study Group  I, C S 
Table 
14.3.1.6.2  All Adverse Events by System Organ Class, 
Preferred Term, Earliest Day of Onset and 
Study Group for Dose 1  I, C S 
Table 
14.3.1.6.3  All Adverse Events by System Organ Class, 
Preferred Term, Earliest Day of Onset and 
Study Group for Dose 2  I, C S 
Table 
14.3.1.6.4  All Adverse Events by System Organ Class, 
Preferred Term, Earliest Day of Onset and 
Study Group for Dose 3   I, C S 
Table 
14.3.1.7.1  Solicited Local Reactogenicity Symptoms by 
Maximum Severity  and Study Group  for 
Doses 1, 2 and 3  I, C S 
Table 
14.3.1.7.2  Solicited Local Reactogenicity Symptoms  by 
Maximum Severity  and Study Group for Dose 
1 I, C S 
Table 
14.3.1.7.3  Solicited Local Reactogenicity Symptoms  by 
Maximum Severity  and Study Group for Dose 
2 I, C S 
Table 
14.3.1.7.4  Solicited Local Reactogenicity Symptoms  by 
Maximum Severity  and Study Group for Dose 
3 I, C S 
Table 
14.3.1.7. 5 Solicited Local React ogenicity Symptoms  by 
Maximum Severity , Study Group and Dose  I, C S 
Table 
14.3.1.8.1  Solicited Systemic Reactogenicity Symptoms  
by Maximum Severity  and Study Group for 
Doses 1, 2 and 3  I, C S 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  50  
   
    Table 
14.3.1.8.2  Solicited Systemic Reactogenicity Symptoms  
by Maximum Severity  and Study Group for 
Dose 1  I, C S 
Table 
14.3.1.8.3  Solicited Systemic Reactogenicity Symptoms  
by Maximum Severity  and Study Group for 
Dose 2  I, C S 
Table 
14.3.1.8.4  Solicited Systemic Reactogenicity Symptoms  
by Maximum Severity  and S tudy Group for 
Dose 3  I, C S 
Table 
14.3.1.8. 5 Solicited Systemic Reactogenicity Symptoms  
by Maximum Severity , Study Group and Dose  I, C S 
Table 
14.3.1.8.6  Solicited Systemic Reactogenicity Symptoms  
by Strongest Relationship to Investigational 
Product  and Study Group for Doses 1, 2 and 3  I, C S 
Table 
14.3.1.8.7  Solicited Systemic Reactogenicity Symptoms  
by Strongest Relationship to Investigational 
Product  and Study Group for Dose 1  I, C S 
Table 
14.3.1.8.8  Solicited Systemic Reactogenicity Symptoms  
by Strongest Relationship to Investigational 
Product  and Study Group for Dose 2  I, C S 
Table 
14.3.1.8.9  Solicited Systemic Reactogenicity Symptoms  
by Strongest Relationship to Investigational 
Product  and Study Group for Dose 3  I, C S 
Table 
14.3.1.9.1  Unsolicited Adverse Events by System Organ 
Class, Preferred Term and Study Group  I, C 
 S 
Table 
14.3.1.9.2  Unsolicited Adverse Events by System Organ 
Class, Preferred Term and Study Group for 
Dose 1  I, C 
 S 
Table 
14.3.1.9.3  Unsolicited Adverse Events by System Organ 
Class, Preferred Term and Study Group for 
Dose 2  I, C 
 S 
Table 
14.3.1.9.4  Unsolicited Adverse Events by System Organ 
Class, Preferred Term and Study Group for 
Dose 3  I, C 
 S 
Table 
14.3.2.1.1  Serious Adverse Events by System Organ 
Class, Preferred Term and Study Group  I, C S 
Table 
14.3.2.1.2  Medically Attended Adverse Events by 
System Organ Class, Preferred Term and 
Study Group  I, C S 
Table 
14.3.2.1.3  Potentially Immune -Mediated Medical 
Conditions by System Organ Class, Preferred 
Term an d Study Group  I, C S 
Table 
14.3.2.1.4  All Adverse Events by System Organ Class, 
Preferred Term and Study Group  Leading to 
Death  I, C S 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  51  
   
    Note: Each table will be created once per applicable population.   In addition, each table will be 
created once to show summaries by study group, and once to show summaries by pooled age or 
arm groups.  
 
  Table 
14.3.2.2.1  All Adverse Events by System Organ Class, 
Preferred Term and Study Group Leading to 
Early Termination of Investigational Product  I, C S 
Table 
14.3.2.2.2  All Adverse Events by System Organ Class, 
Preferred Term and Study Group Leading to 
Study Withdrawal  I, C S 
Table 
14.3.3.1  Investigational Product Site Examination by 
Study Group for Dose 1  C S 
Table 
14.3.3.2  Investigational Product Site Examination  by 
Study Group for Dose 2  C S 
Table 
14.3.3.3  Investigational Product Site Examination  by 
Study Group for Dose 3  C S 
Table 
14.3.4.1  Chemistry, Hematology and Urinalysis 
Clinical Laboratory Results  by Study  Group  C S 
Table 
14.3.4.2  Shift from Baseline in Grading of  Chemistry, 
Hematology and Urinalysis Clinical 
Laboratory Results  by Study Group  C S 
Table 
14.3.5.1  Vital Sign Parameters by Study Group   C S 
Table 
14.3.5.2  Shift from Baseline in Grading of Vital Sign 
Parameters by Study Group  C S 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  52  
   
    Listings 
Listing 
Number Listing Title  Applicable 
Reports 
(C=Final 
CSR) Applicable 
Populations 
(NR=Not 
Randomized, 
R=Randomized, 
S=Safety,  
F=IFAP,     
P=IPPP 
M=MIPPP ) 
Listing 
16.2.1.1  Disposition  C R 
Listing 
16.2.1.2  Visit Completion  C R 
Listing 
16.2.1.3  Analysis  Populations  C R 
Listing 
16.2.1.4  Reasons for Subject Ineligibility  for 
Enrollment  C NR 
Listing 
16.2.1.5  Reasons for Subject Ineligibility for 2nd 
Investigational Product Administration  C S 
Listing 
16.2.1.6  Reasons for Subject Ineligibility for 3rd 
Investigational Product Administration  C S 
Listing 
16.2.2.1  Protocol Deviations  C R 
Listing 
16.2.4.1  Demographics and Baseline Physical 
Characteristics  C S 
Listing 
16.2.4.2  Medical History  C S 
Listing 
16.2.4.3  Immunization History  C S 
Listing 
16.2.4. 4 Prior and Concomitant Medications  C S 
Listing 
16.2.4.5  Concomitant Immunizations  C S 
Listing 
16.2.5  Investigational Product Administration 
Adherence  C S 
Listing 
16.2.6  Serum TNA NF 50, TNA ED 50 and ELISA anti -
PA IgG Antibody Levels  C F 
Listing 
16.2.7.1  Adverse Events  C S 
Listing 
16.2.7.2  Serious Adverse Events  C S 
Listing 
16.2.7.3  Medically Attended Adverse Events  C S 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  53  
   
    Listing 
16.2.7.4  Potentially Immune -Mediated Medical 
Conditions  C S 
Listing 
16.2.7.5  Adverse Events Leading to Death  C S 
Listing 
16.2.7. 6 Potentially Life-Threatening (Grade 4) Adverse 
Events  C S 
Listing 
16.2.7. 7 Adverse Events Leading to Early Termination 
of Investigational Product  C S 
Listing 
16.2.7. 8 Adverse Leading to Study Withdrawal  C S 
Listing 
16.2.7. 9 Adverse Event Verbatim Text Coding List to 
Preferred Term  C N/A 
Listing 
16.2.7. 10 Investigational Product Site Examination  C S 
Listing 
16.2.7.11  Participant -reported Diary Card Measurements 
of Investigational Product Site 
Erythema/Redness and Induration/Swelling  C S 
Listing 
16.2.8.4  Chemistry, Hematology and Urinalysis Clinical 
Laboratory Results  C S 
Listing 
16.2.9.1  Vital Signs  C S 
Listing 
16.2.9.2  Electrocardiogram Results  C S 
Listing 
16.2.9.3  High -Sensitivity  C-Reactive Protein Assay 
Results  for Subjects ‚â•66 Years  C S 
Listing 
16.2.9.4  Screening HIV Antibody, Hepatitis B Surface 
Antigen and Hepatitis C Antibody Results  C S 
Listing 
16.2.9.5  Screening Hemoglobin A1C Results  C S 
Listing 
16.2.9. 6 Screening Urine Drug Test  Results  C S 
Listing 
16.2.9. 7 Autoantibody Assay Results  C S 
Listing 
16.2.9. 8 Urine Pregnancy Assessment  C S 
Listing 
16.2.9. 9 Pregnancies  C S 
Note: Additional listings may be produced based on actual study results.  
 
 
 
 
 
 
 
HHS/ASPR/ BARDA   BioThrax and AV7909  
SAP: BP -C-17001 Version 2.0   11 April 2019  
CONFIDENTIAL AND PROPRIETARY  54  
   
     
 
  
Figures 
Note: Each figure will be created once per applicable population.  In addition, each figure will be 
created once to show data by study group, and once to show data by pooled age or arm groups.  
 
 
 Figure 
Number Figure Title  Applicable 
Reports 
(I=Interim, 
C=Final CSR ) Applicable 
Populations 
(R=Randomized, 
S=Safety, 
F=IFAP,  
P=IPPP 
M=MIPPP ) 
Figure 
14.2.1.1  TNA NF 50 Antibody Levels Plot of 
Geometric Mean Levels and 95% CI Over 
Time  I, C P, M 
Figure 
14.2.1.2  Seroprotection by TNA NF 50 Antibody 
Levels at Visit 10 (Day 64)  I, C F, P, M 
Figure 
14.2.1.3  TNA NF 50 Antibody Levels Reverse 
Cumulative Distribution Plot at Visit 10 
(Day 64)  I, C P, M 
Figure 
14.2.2.1  TNA ED 50 Antibody Levels Plot of 
Geometric Mean Levels and 95% CI Over 
Time  I, C P, M 
Figure 
14.2.2.2  TNA ED 50 Antibody Levels Reverse 
Cumulative Distribution Plot at Visit 10 
(Day 64)  I, C P, M 
Figure 
14.2.3.1  ELISA anti -PA IgG  Antibody Levels Plot 
of Geometric Mean Levels and 95% CI 
Over Time  I, C P, M 
Figure 
14.2.3.2  ELISA anti-PA IgG   Antibody Levels 
Reverse Cumulative Distribution Plot at 
Visit 10 (Day 64)  I, C P, M 
Figure 
14.2.4. 1 TNA NF 50 and  ELISA anti -PA IgG 
Antibody Titer Scatter Plot  at Visit 10 
(Day 64)  C P, M 
Figure 
14.2.4. 2 TNA ED 50 and  ELISA anti -PA IgG 
Antibody Titer Scatter Plot  at Visit 10 
(Day 64)  C P, M 